Quarterly Updates1 Nov 2026, 06:30 pm
Sai Parenterals: No IPO Fund Use Deviation for Q2 FY27
AI Summary
Sai Parenterals Limited has filed a statement confirming no deviation or variation in the utilization of its Initial Public Offer (IPO) proceeds for the quarter ended September 30, 2026. The company raised ₹2,850 million through its IPO between March 24-27, 2026. The report details the utilization against original objects, showing funds used for capacity expansion, R&D, loan repayment, and working capital. No significant deviations were noted, and the Audit Committee and auditors provided NIL comments.
Key Highlights
- No deviation in IPO fund utilization for Q2 FY27 reported.
- Company raised ₹2,850 million via IPO in March 2026.
- Funds utilized for expansion, R&D, debt repayment, and working capital.
- No adverse comments from Audit Committee or auditors.
- Monitoring agency is M/s. India Ratings & Research Private Limited.
Price Impact
More from SAIPARENT